Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

GlobeNewswire November 11, 2020

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire October 26, 2020

InvestmentPitch Media Video Discusses Revive Therapeutics' supply agreement with Havn Life Sciences for Psychedelic Compounds - Video Available on Investmentpitch.com

Newsfile October 21, 2020

The Potential $100 Billion Psychedelics Boom Investors Should Watch

Livemoney October 20, 2020

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

GlobeNewswire October 20, 2020

The StockTalk Cannabis Report: Oct. 2, 2020

Dave Jackson October 2, 2020

Surging Psychedelic Stock Backed by University Study

Stockhouse Editorial October 1, 2020

The World May be Nearing Treatments for the Growing Pandemic

Livemoney September 29, 2020

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire September 29, 2020

These Could be Some of the Most Valuable Psychedelic Stocks

Livemoney September 24, 2020

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

GlobeNewswire September 21, 2020

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

GlobeNewswire September 16, 2020

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

GlobeNewswire September 2, 2020

IIROC Trade Resumption - RVV

Canada NewsWire August 31, 2020

IIROC Trading Halt - RVV

Canada NewsWire August 31, 2020

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

GlobeNewswire August 31, 2020

Global Pandemic: This is When the World May be Able to Return to Normal

Livemoney August 27, 2020

IIROC Trade Resumption - RVV

Canada NewsWire August 26, 2020

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

GlobeNewswire August 26, 2020

IIROC Trading Halt - RVV

Canada NewsWire August 26, 2020